Key Highlights

  • Aptevo Therapeutics (NASDAQ:APVO) traded at USD 1.43, up 11.72%, in pre-market trading on Wednesday, October 28, 2026, following its Monday, October 26, 2026 release on stem cell transplant outcomes with mipletamig.
  • For the quarter ended June 30, 2026, reported on Friday, August 14, 2026, the company held cash and equivalents of USD 9.8 million and raised USD 0.6 million through its standby equity purchase facility.
  • In the Monday, October 26, 2026 release, 10 of 47 patients treated with the mipletamig, venetoclax and azacitidine combination proceeded to donor stem cell transplant, and the RAINIER work is expected to complete by year-end 2026.
  • The warrant inducement and private placement of August 2026 raised about USD 4.5 million gross, and the pre-market quote is a thin snapshot that can change before the open at 9:30 a.m. ET.

What Triggered the Pre-Market Gain

Aptevo Therapeutics (NASDAQ:APVO) is a clinical-stage biotechnology company working on multispecific antibodies for blood cancers and solid tumours. In the pre-market snapshot of Wednesday, October 28, 2026 it was quoted at USD 1.43, a gain of 11.72%, which reverses the pre-market decline seen on Tuesday, October 27, 2026 and implies a prior close near USD 1.28 by simple arithmetic on the snapshot. Its most recent company item is the release of Monday, October 26, 2026 at 8:05 a.m. ET, reporting that 10 of 47 patients given the mipletamig combination for acute myeloid leukaemia proceeded to donor stem cell transplant, a potentially curative route. Nothing dated Tuesday, October 27, 2026 or Wednesday, October 28, 2026 was found. Pre-market quotes may change before the open.

How the Transplant Data and Financing Shape the Move

According to the Monday, October 26, 2026 release, nine of the transplanted patients came from the Phase 1b RAINIER trial and one from a completed dose expansion trial; Aptevo Therapeutics (NASDAQ:APVO) intends to take up next steps with regulators in the first half of 2027. Its quarterly update of Friday, August 14, 2026 showed cash and equivalents of USD 9.8 million at June 30, 2026, plus a USD 1.5 million non-dilutive grant and a 50/50 radiopharmaceutical collaboration with Niowave. A warrant inducement and private placement at USD 4.03 per share was announced on Wednesday, August 12, 2026, with 254,922 warrants exercised. Net loss and earnings per share were not among the figures cited.

Bull and Bear Readings

The optimistic reading rests on the transplant outcomes, which suggest a share of patients on the combination can reach a potentially curative procedure, and on the earlier 93% clinical benefit rate in frontline TP53-mutated disease reported on Thursday, September 3, 2026. The cautious reading rests on small patient numbers, a cash balance of USD 9.8 million at June 30, 2026 and the dilution that followed the August placement. Specific risks include further equity issuance, trial execution, competition in acute myeloid leukaemia and thin liquidity. Watch the Federal Reserve decision due later on Wednesday, October 28, 2026, the SITC Annual Meeting in Phoenix from Wednesday, November 4, 2026 to Sunday, November 8, 2026 and the regulatory discussion planned for the first half of 2027.

Where Things Stand

Aptevo Therapeutics (NASDAQ:APVO) gained 11.72% before the open on Wednesday, October 28, 2026. The advance follows the transplant data of Monday, October 26, 2026, although a rebound from the prior session's dip may also play a part. Ten transplanted patients out of 47 treated, and cash of USD 9.8 million at June 30, 2026, are the two numbers to hold onto. Upcoming catalysts include the Federal Reserve decision later on Wednesday, October 28, 2026, the SITC meeting starting Wednesday, November 4, 2026 and RAINIER's year-end completion. Pre-market prices can change, and this is not investment advice.